Live Varicella Zoster Vaccine Safe, Effective with TNF Inhibitors

(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1 Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or... [Read More]

Source: The Rheumatologist - October 6, 2021 Category: Rheumatology Authors: Lisa Rapaport Tags: Biologics & Biosimilars Drug Updates live vaccine varicella zoster vaccine varicella zoster virus Source Type: research